Navigation Links
Cellzome Technology Used to Unravel Novel Regulatory Mechanism in Cancer Signaling Pathway
Date:9/16/2009

HEIDELBERG, Germany, September 16 /PRNewswire/ --

- Integrated Chemical Genetics and Proteomics Approach Identifies new Potential Drug Targets in Wnt Pathway

Cellzome announces today, the publication entitled "Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling"** is now available online in Nature.

The paper describes how Cellzome's quantitative chemical proteomics platform was used to identify a small molecule which plays a critical role in the regulation of the Wnt pathway. The small molecule stabilizes axin by inhibiting the poly-ADP-ribosylating enzymes tankyrase 1 and tankyrase 2. Both tankyrase isoforms interact with a highly conserved domain of axin and stimulate its degradation through the ubiquitin-proteasome pathway. Thus, the study provides new mechanistic insights into the regulation of axin protein homeostasis and presents new avenues for therapeutic intervention in this key cancer pathway. This transforming science was conducted as part of the collaboration between Cellzome and Novartis Institutes for Biomedical Research (NIBR).

Dr. David Simmons, CSO of Cellzome, said: "This paper shows the powerful insights provided by Cellzome's proprietary chemical proteomics technology platform. Our platform also includes Kinobeads(TM) which we use for the discovery and development of a new generation of kinase inhibitors and Episphere(TM) for the discovery of novel drug candidates for epigenetic targets."

** Huang, S., et.al. "Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling", Nature, 10.1038/nature08356, 2009.

About Cellzome Inc.

Cellzome is a privately-owned drug discovery and development company identifying a new generation of kinase-targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads(TM), a proprietary technology for the screening and profiling of kinase inhibitors in physiologically-relevant cells and tissues. The most advanced program, targeting PI3K(gamma), is anticipated to enter the clinic in 2010, and several other programs are in early preclinical testing.

Cellzome is expanding its distinctive technology, in a novel form called Episphere(TM), to the discovery and development of novel drug candidates for epigenetic targets in their protein complexes.

Cellzome has significant collaborations with GSK and Johnson & Johnson. Its holding company is domiciled in the US and it employs about 90 people at its two laboratories in Cambridge, UK and Heidelberg, Germany.


'/>"/>
SOURCE Cellzome Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GlaxoSmithKline and Cellzome Announce Major Strategic Alliance
2. Abbott Wins Top Honor in Wall Street Journal Technology Innovation Awards
3. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
4. China Agro-Technology Holdings Announces Launch of Agricultural Biotech Website
5. Dr M Group Selects Health Robotics Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia
6. Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
7. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
8. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
9. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
10. Tata Interactive Systems Initiates Vertical-Focused Learning Solutions for Health Care, Pharmaceutical, and Biotechnology
11. Hyland Software Provides Grant Assistance to Kick-Start Technology Projects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Koert van Mensvoort - founder of the Next Nature Network and ... has written a ,Letter to Humanity, in support of International Earth ... and victim to its own technology, but to employ technology to enhance our ... ... of the Next Nature Network and Fellow of ‘Next Nature’ at the University ...
(Date:4/19/2017)... ... April 18, 2017 , ... The Vibrating ... key device for generating monodisperse droplets of known diameters for research applications such ... monodisperse solid particles by drying monodisperse droplets. , The VOAG requires forcing ...
(Date:4/19/2017)... , ... April 18, 2017 , ... ... Halo Labs . The move comes after the company changed focus to making ... our new brand and our new technology,” says CEO Robert Hart. Founders Bernardo ...
(Date:4/19/2017)... ... April 19, 2017 , ... WHO: Peggy Lillis ... through education and advocacy. Founded in 2010 in memory of a single-parent mom ... foundation has become the most-consulted source for patient-focused information on C. diff infections ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
Breaking Biology News(10 mins):